Vir Bio Swings to Q2 Profit on Astellas Deal, ECLIPSE Program Fully Enrolled
VIR has more than doubled off its 52-week low of $4.155.
Summary
Vir Biotechnology swung to a Q2 profit of $80.1M on $239.3M in Astellas license revenue. The ECLIPSE program is fully enrolled with pivotal data due Q4 2026. Cash stands at $1.01B. CFO departure adds to executive turnover.
Key Events · Earnings and Guidance · VIR
-
Q2 Profit Driven by Astellas Deal
Net income of $80.1M vs. a $111.0M loss in Q2 2025, fueled by $239.3M in license revenue recognized from the Astellas collaboration for VIR-5500.
-
ECLIPSE Program Fully Enrolled
All three ECLIPSE trials are fully enrolled. Topline data from the pivotal ECLIPSE 1 trial is expected in Q4 2026, with ECLIPSE 2 and 3 data in Q1 2027.
-
Strong Cash Position
Cash, cash equivalents, and investments totaled $1.01B as of June 30, 2026, providing runway for at least 12 months.
-
CFO Departure
CFO Jason O'Byrne resigned effective August 3, 2026. CAO Brent Sabatini appointed interim principal financial officer. This follows the recent CMO departure.
Analysis · VIR · Life Sciences
A sharp reversal from last year's $111.0 million loss, Vir Biotechnology posted net income of $80.1 million for Q2 2026, powered by the recognition of $239.3 million in license revenue from the Astellas collaboration. The balance sheet remains robust, with $1.01 billion in cash and investments at quarter-end, providing a solid runway. Full enrollment in the ECLIPSE registrational program for chronic hepatitis delta sets the stage for a major near-term catalyst: topline data from the pivotal ECLIPSE 1 trial are expected in Q4 2026. On the leadership front, the announced departure of CFO Jason O'Byrne adds to a recent string of executive changes. Separately, a second amendment to the Sanofi license agreement broadens the licensed know-how and patent portfolio for the PRO-XTEN masking platform.
At the time of this filing, VIR was trading at $9.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $4.16 to $11.66. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.